Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.52 |
| ▸ | NAMPT | P43490 | 5/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8214411 | 0.94 | GPR119 (0.56) | HDAC1HDAC6GPR119NAMPTTRPV1 | |
| SCHEMBL8218928 | 0.91 | HDAC1 (0.56) | HDAC1HDAC6GPR119NAMPTTRPV1 | |
| SCHEMBL8207926 | 0.91 | TRPV1 (0.51) | HDAC1HDAC6GPR119TRPV1 | |
| SCHEMBL8217952 | 0.89 | HDAC1 (0.52) | HDAC1HDAC6GPR119NAMPTTRPV1 | |
| SCHEMBL8224724 | 0.88 | HDAC1 (0.53) | HDAC1HDAC6GPR119NAMPTTRPV1 | |
| SCHEMBL8224617 | 0.87 | HDAC1 (0.53) | HDAC1HDAC6GPR119NAMPTMAPT | |
| SCHEMBL8224619 | 0.85 | CACNA1H (0.46) | HDAC1HDAC6GPR119MEN1KMT2A | |
| SCHEMBL8224919 | 0.85 | HDAC1 (0.57) | HDAC1HDAC6GPR119NAMPTKDM1A | |
| SCHEMBL8224778 | 0.85 | GPR119 (0.52) | HDAC1HDAC6GPR119NAMPTTRPV1 | |
| SCHEMBL8224767 | 0.84 | CACNA1H (0.52) | HDAC1HDAC6GPR119NAMPTGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076750-A1 | Azetidinone Derivatives and Methods of Use Thereof | SCHERING CORPORATION | 2008-03-27 | — | — | US | disclosed |
| WO-2008033460-A2 | TREATING PAIN, DIABETES, AND LIPID METABOLISM DISORDERS | SCHERING CORPORATION (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076750-A1 | Azetidinone Derivatives and Methods of Use Thereof | LIPC, CES1, ZDHHC20 | HDAC1 937/4885HDAC6 2818/4885GPR119 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.